Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZoetisXSWX:ZTS +2.39%63 Forward PE Ratio is 10.97 as of Jul. 17, 2026. GuruFocus rates XSWX:ZTS with a GF Score™ of 63/100 and a GF Value™ of CHF156.38 (Significantly Undervalued). Among 410 Drug Manufacturers companies, Zoetis ranks better than 72.68% on this metric.
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Zoetis Forward PE Ratio Related Terms
Zoetis Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Zoetis's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zoetis Forward PE Ratio Chart
Zoetis Annual Data
Trend
Forward PE Ratio
Zoetis Quarterly Data
2026-03
Forward PE Ratio
17.13
XSWX:ZTS vs UTHR, VTRS, NBIX: Forward PE Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zoetis's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zoetis Forward PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zoetis's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Zoetis's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Zoetis (XSWX:ZTS) has a Forward PE Ratio of 10.97 as of Jul. 17, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Zoetis and its competitors. According to the industry distribution chart, Zoetis ranks #112 out of 410 companies in the Drug Manufacturers industry, placing it in the top 27.3%.
Is Zoetis' Forward PE Ratio too high?
Zoetis' current Forward PE Ratio is 10.97. The Drug Manufacturers industry median Forward PE Ratio is 17.27. Zoetis' value of 10.97 is 36.5% below this industry median. Based on the distribution chart, Zoetis ranks #112 out of 410 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Zoetis has a GF Score™ of 63/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zoetis' Forward PE Ratio compare to UTHR and VTRS?
According to the Drug Manufacturers industry distribution chart, Zoetis ranks #112 out of 410 companies for Forward PE Ratio. This puts Zoetis in the upper half of its industry. The industry median Forward PE Ratio is 17.27. Zoetis' value of 10.97 is 36.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Drug Manufacturers company?
The median Forward PE Ratio among Drug Manufacturers companies is 17.27, based on 410 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zoetis's current Forward PE Ratio of 10.97 is 36.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Zoetis and its competitors. For the Drug Manufacturers industry, the median Forward PE Ratio is 17.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zoetis's current Forward PE Ratio is 10.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zoetis stock overvalued right now?
Based on GuruFocus' analysis, Zoetis (XSWX:ZTS) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF156.38, compared to a current price of CHF61.79 — trading 60.5% below its estimated fair value. The current Forward PE Ratio is 10.97 and 36.5% below the Drug Manufacturers industry median of 17.27. Zoetis' overall GF Score™ is 63/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Zoetis (XSWX:ZTS), the current Forward PE Ratio is 10.97 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zoetis (XSWX:ZTS) Overvalued in 2026?
Based on GuruFocus' analysis, Zoetis stock appears to be undervalued.
The current stock price of CHF61.79 is trading 60.5% below its estimated GF Value™ of CHF156.38.
GuruFocus considers Zoetis to be Significantly Undervalued.
Key valuation signals for XSWX:ZTS:
Forward PE Ratio: 10.97
GF Value™: CHF156.38 vs. price of CHF61.79 (60.5% below fair value)
Industry Position: 36.5% below the Drug Manufacturers median (#112 of 410)
No single metric tells the full story. See the XSWX:ZTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
63GF Score
Get the complete analysis for XSWX:ZTS
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ZTS has been successfully added to your 
